Anterix Croissance future

Future contrôle des critères 2/6

Anterix devrait augmenter ses bénéfices et son chiffre d'affaires de 22.9% et de 20.1% par an respectivement. Le BPA devrait croître de de 20.5% par an. Le rendement des capitaux propres devrait être -89.6% dans 3 ans.

Informations clés

22.9%

Taux de croissance des bénéfices

20.5%

Taux de croissance du BPA

Telecom croissance des bénéfices	18.3%
Taux de croissance des recettes	20.1%
Rendement futur des capitaux propres	-89.6%
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Anterix Inc.'s (NASDAQ:ATEX) CEO Pay Packet

Jul 31

Steel City Capital Investments - Anterix: Potential Capital Return To Shareholders?

Feb 28

Anterix (NASDAQ:ATEX) Is In A Strong Position To Grow Its Business

Dec 16

Anterix (NASDAQ:ATEX) Is In A Strong Position To Grow Its Business

Aug 11

Anterix: Spectrum Opportunity Keeps The Risk/Reward Skewed Favorably

Jul 05

Anterix (NASDAQ:ATEX) Is In A Good Position To Deliver On Growth Plans

Mar 30

Chief Regulatory & Communications Officer Chris Guttman-McCabe Just Sold A Bunch Of Shares In Anterix Inc. (NASDAQ:ATEX)

Feb 23

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ATEX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2027	10	-39	42	43	1
3/31/2026	7	-11	29	55	2
3/31/2025	6	-51	-2	15	3
9/30/2024	6	-37	17	35	N/A
6/30/2024	5	-23	30	48	N/A
3/31/2024	4	-9	25	42	N/A
12/31/2023	4	16	6	27	N/A
9/30/2023	3	7	-32	-7	N/A
6/30/2023	2	-5	-51	-26	N/A
3/31/2023	2	-16	-54	-27	N/A
12/31/2022	2	-43	-60	-28	N/A
9/30/2022	1	-48	-15	13	N/A
6/30/2022	1	-39	-10	18	N/A
3/31/2022	1	-38	-9	18	N/A
12/31/2021	1	-37	18	38	N/A
9/30/2021	1	-37	-26	-8	N/A
6/30/2021	1	-51	-26	-12	N/A
3/31/2021	1	-54	-24	-10	N/A
12/31/2020	1	-55	-45	-28	N/A
9/30/2020	1	-52	-43	-28	N/A
6/30/2020	1	-43	-40	-26	N/A
3/31/2020	2	-38	-35	-28	N/A
12/31/2019	3	-35	-29	-27	N/A
9/30/2019	4	-35	-26	-25	N/A
6/30/2019	5	-39	-27	-25	N/A
3/31/2019	6	-42	-25	-23	N/A
12/31/2018	7	-41	-24	-22	N/A
9/30/2018	7	-33	-24	-23	N/A
6/30/2018	7	-29	N/A	-23	N/A
3/31/2018	6	-25	N/A	-22	N/A
12/31/2017	6	-30	N/A	-23	N/A
9/30/2017	6	-37	N/A	-23	N/A
6/30/2017	5	-37	N/A	-23	N/A
3/31/2017	5	-39	N/A	-27	N/A
12/31/2016	4	-32	N/A	-26	N/A
9/30/2016	4	-30	N/A	-25	N/A
6/30/2016	4	-28	N/A	-22	N/A
3/31/2016	4	-22	N/A	-20	N/A
12/31/2015	3	-21	N/A	-14	N/A
9/30/2015	3	-19	N/A	-11	N/A
6/30/2015	3	-16	N/A	-4	N/A
3/31/2015	3	-15	N/A	4	N/A
12/31/2014	3	-9	N/A	4	N/A
9/30/2014	3	-6	N/A	4	N/A
6/30/2014	3	-3	N/A	0	N/A
3/31/2014	4	-1	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ATEX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ATEX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ATEX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ATEX ( 20.1% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ATEX ( 20.1% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ATEX devrait être non rentable dans 3 ans.

Anterix Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates fall by 12%

No longer forecast to breakeven

Price target increased by 13% to US$78.33

Consensus estimates of losses per share improve by 75%

Consensus estimates of losses per share improve by 38%

Consensus revenue estimates fall by 70%

Recent updates

Insider recently sold US$183k worth of stock

Insider notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Anterix Inc. to Report Q2, 2025 Results on Nov 13, 2024

Anterix Announces Chief Executive Officer Changes

Consensus revenue estimates fall by 12%

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued

Here's Why Shareholders May Want To Be Cautious With Increasing Anterix Inc.'s (NASDAQ:ATEX) CEO Pay Packet

Anterix Inc. to Report Q1, 2025 Results on Aug 06, 2024

Anterix Inc., Annual General Meeting, Aug 06, 2024

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Price target increased by 13% to US$78.33

Full year 2024 earnings: EPS and revenues miss analyst expectations

Anterix Inc. to Report Q4, 2024 Results on Jun 26, 2024

Chief Financial Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 75%

We Think That There Are Issues Underlying Anterix's (NASDAQ:ATEX) Earnings

Investor sentiment improves as stock rises 29%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Anterix Inc. Announces Resignation of Paul Saleh from the Board of Directors, Member of Audit Committee and the Strategy Committee

Anterix Inc. to Report Q3, 2024 Results on Feb 14, 2024

Independent Director recently bought US$4.1m worth of stock

Consensus estimates of losses per share improve by 38%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Anterix Names Wassim Akhdar as Senior Vice President of Product and Innovation

Anterix Inc. to Report Q2, 2024 Results on Nov 13, 2023

Anterix Inc. (NasdaqCM:ATEX) announces an Equity Buyback for $250 million worth of its shares.

Consensus revenue estimates fall by 70%

New minor risk - Profitability

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Anterix Inc. to Report Q1, 2024 Results on Aug 02, 2023

Anterix Inc., Annual General Meeting, Aug 08, 2023

We're Hopeful That Anterix (NASDAQ:ATEX) Will Use Its Cash Wisely

Insider recently sold US$251k worth of stock

Consensus revenue estimates increase by 37%

Insider notifies of intention to sell stock

New major risk - Financial position

Full year 2023 earnings released: US$0.87 loss per share (vs US$2.07 loss in FY 2022)

Anterix Inc. to Report Q4, 2023 Results on Jun 14, 2023

Executive Chairman recently sold US$150k worth of stock

Price target decreased by 7.7% to US$69.40

Less than half of directors are independent

No longer forecast to breakeven

Consensus revenue estimates increase by 68%

Anterix Inc. Appoints Jeffery Altman to Its Board of Directors as an Independent Director and Member of the Strategy Committee

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Anterix Inc. to Report Q3, 2023 Results on Feb 09, 2023

We're Not Worried About Anterix's (NASDAQ:ATEX) Cash Burn

Insider recently sold US$302k worth of stock

Consensus revenue estimates increase by 37%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Anterix Inc. to Report Q2, 2023 Results on Nov 08, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anterix (NASDAQ:ATEX) Is In A Strong Position To Grow Its Business

Anterix Inc. to Report Q1, 2023 Results on Aug 08, 2022

Anterix Inc., Annual General Meeting, Aug 10, 2022

Executive Chairman exercised options and sold US$376k worth of stock

Insider recently sold US$244k worth of stock

Forecast to breakeven in 2025

No longer forecast to breakeven

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Anterix Announces the Launch of New Integrated Platform to Drive Industrywide 900 MHz Private Broadband Innovation and Solutions

Anterix Inc. to Report Q4, 2022 Results on May 20, 2022

Anterix Inc. Announces Resignation of Hamid Akhavan from the Board, Effective April 1, 2022

Steel City Capital Investments - Anterix: Potential Capital Return To Shareholders?